NEW
YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments, is proud to announce the granting of a U.S. patent for
its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent
secures the company's intellectual property rights to its novel
therapeutic approach, as Hoth accelerates preparations for clinical
trials.
HT-ALZ represents a breakthrough in Alzheimer's treatment,
specifically targeting the Substance P/Neurokinin-1 Receptor
pathway. This pathway is known to play a critical role in
neuroinflammation, which is increasingly recognized as a driving
factor in the progression of Alzheimer's disease. Preclinical
studies have shown promising results, including reduced
neuroinflammation and significant improvements in cognitive
functions such as memory and learning.
The patent solidifies Hoth's leadership in the development of
Alzheimer's therapies and paves the way for the next phase of human
clinical trials. Formulation of HT-ALZ for these trials is
currently underway, with the goal of advancing this promising
treatment to patients as swiftly as possible.
Next Steps
As Hoth Therapeutics completes the formulation phase, the
company will look to prepare clinical trials to further validate
HT-ALZ's efficacy in humans. The upcoming trials will focus on
demonstrating the drug's safety, tolerability, and effectiveness in
slowing or reversing the cognitive decline associated with
Alzheimer's disease.
Robb Knie, CEO of Hoth
Therapeutics, commented, "This patent marks a significant
achievement for Hoth as we progress HT-ALZ from the lab to clinical
development. The preclinical data on neuroinflammation reduction
and cognitive improvement offer great hope, and we are excited to
take the next critical steps toward delivering a potentially
life-changing therapy to Alzheimer's patients."
About HT-ALZ
HT-ALZ represents a novel approach in Alzheimer's research,
focusing on the modulation of neuroinflammation, unlike many
treatments that focus solely on amyloid plaques. Preclinical data
has shown that HT-ALZ effectively reduces reactive astrocytes in
the brain, cells that contribute to the inflammatory processes seen
in Alzheimer's, leading to improved cognitive outcomes in
experimental models.
For more information about Hoth Therapeutics and HT-ALZ, please
visit www.hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit
https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release
includes forward-looking statements based upon Hoth's
current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth
may not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors"
in Hoth's most recent Annual Report on Form 10-K and Hoth's
other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimers-treatment-and-prepares-for-clinical-trials-of-ht-alz-with-formulation-now-underway-302275779.html
SOURCE Hoth Therapeutics, Inc.